Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | FOXO1 | Q12778 | 9/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 10/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25429654 | 1.00 | ACHE (0.49) | ACHEFOXO1DGAT1KCNH2ADORA2A | |
| SCHEMBL29524383 | 0.92 | FOXO1 (0.48) | ACHEFOXO1DGAT1KCNH2ADORA2A | |
| SCHEMBL25426157 | 0.92 | FOXO1 (0.48) | ACHEFOXO1DGAT1KCNH2ADORA2A | |
| SCHEMBL25429317 | 0.90 | MAPT (0.53) | ACHEFOXO1DGAT1KCNH2SOAT1 | |
| SCHEMBL29523779 | 0.90 | MAPT (0.53) | ACHEFOXO1DGAT1KCNH2SOAT1 | |
| SCHEMBL25429106 | 0.90 | ACHE (0.49) | ACHEFOXO1DGAT1KCNH2ADORA2A | |
| SCHEMBL29524325 | 0.90 | ACHE (0.49) | ACHEFOXO1DGAT1KCNH2ADORA2A | |
| SCHEMBL29524536 | 0.89 | FOXO1 (0.52) | ACHEFOXO1 | |
| SCHEMBL25430099 | 0.89 | FOXO1 (0.52) | ACHEFOXO1 | |
| SCHEMBL25426785 | 0.88 | ACHE (0.49) | ACHEFOXO1DGAT1KCNH2ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK | 2023-12-28 | — | — | US | disclosed |
| EP-4217355-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Forkhead Biotherapeutics, inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022066938-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FORKHEAD BIOTHERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FOXO1, FOXO3, GCKR | ACHE 4877/4885FOXO1 1/4885DGAT1 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.